Document:

Amended Consulting Agreement - Hendrix Bodden

Exhibit 4.1(e) 
 
Amendment to Consulting Agreement of September 24, 2002 
 
February 17, 2003 
 
Mr. Hendrix H. Bodden 
Principal 
Strategic Business Initiatives 
1700
California Ave Suite 601 
San Francisco, California 94109 
 
Dear Mr. Bodden, 
 
The within is to confirm our understanding and agreement as February 17, 2003 wherein Strategic Business Systems (SBI) and their principal, Hendrix
Bodden, have agreed to settle amounts owed by Calptye Biomedical Corporation (the Company) under the previously executed Professional Services Agreement and Calypte Biomedical IT Project Statement of Work both dated September 4, 2002. 
 
Whereas the Terms and Conditions section of the Statement of Work provided for
payment of seven installments totaling $335,000 of which the Company has satisfied three installments for a total of $155,000, leaving an unpaid balance of $180,000. 
 
In consideration for settlement of the outstanding balance of $180,000, the Company agrees to pay SBI the sum of $45,000 in
cash and to issue to SBI’s principal one million shares of Calptye Biomedical Corporation non-assessable and fully paid common stock $.001 par value. SBI understands that the shares are unregistered and restricted and the Company agrees to
provide cost free piggy-back registration rights. SBI may elect to have said shares replaced with shares from the Company Stock Option Plan, in the event that shares in the Stock Option Plan become approved, available and free trading prior to the
effective registration provided by the piggy-back registration rights. 
 
The Company also agrees to pay approved and outstanding expenses totaling $2906.66, on or before February 21, 2003, for a total cash payment of $47,906.66. 
 
SBI agrees to provide the Company a final detailed copy of the Requirements Definition and Implementation Matrix as
contemplated under the Statement of Work on or before February 21, 2003. 
 
Both the Company and SBI mutually agree that, subject to the above, all deliverables and amounts due as contemplated by the agreements have been satisfied in their entirety. 
 

20 

The Company and SBI further agree that all information regarding this settlement and agreement are to
remain confidential. 
 
If the within meets with your understanding
and agreement, please execute a copy of same. 
 
Very truly yours,

 
CALPTYE BIOMEDICAL CORPORATION 
 
/s/    Anthony J. Cataldo 
Anthony J. Cataldo 
Executive Chairman

 
Agreed To: 
 
STRATEGIC BUSINESS INITIATIVES 
 
/s/    Hendrix Bodden 
 
Hendrix H. Bodden 
Principal 
 

21Consulting Agreement - Cliff Brune

 
Exhibit 4.1(f)

 
Consulting Agreement of March 14, 2003

 
March 14, 2003 
 
Mr. Anthony J. Cataldo 
Executive Chairman 
Calypte Biomedical
Corporation 
1265 Harbor Bay Parkway 
Alameda, CA 94502 
 
Dear Tony, 
 
As a result of our most recent conversation regarding the status of Calypte
and your plans to effect a reorganization and downsizing, I submit this letter to serve as my resignation, effective immediately. I will consult for the company in a transition role for the next 30 days. This resignation letter is being provided at
your request, subject to the previous obligations of the company noted below, as any termination by you would require 30 days proper written notice as provided by our employment agreement dated January 2, 2003. 
 
The agreement also provided for 200,000 fully vested options, which I have not
been issued. I am hereby requesting and you agree, that in lieu of this, 240,000 fully vested warrants at .025 (two and one half cents) and with a term of 1 year be granted and be provided immediately, for services that I will provide as a
consultant. You further agree to register these with the upcoming S-8 filing during March 2003. 
 
Further, I have submitted and approved expenses outstanding totaling $2591.76, which are due and payable immediately. 
 
This resignation is being tendered only with the understanding that you will, by March 21, 2003, satisfy the outstanding
obligations noted above. In the event they are not satisfied by this date, the resignation will not be in effect, and the company will be bound by the 30- day proper written notice requirement and any and all other obligations provided for in the
employment agreement. 
 
As a shareholder, I continue to wish the
Company and its employees the best, and trust your plans for its future are successful. 
 
Respectfully, 
 
/s/    Cliff Brune 
Cliff Brune 
 
Agreed and Accepted: /s/    Richard D. Brounstein

                                     
 Richard Brounstein, Calypte CFO 
 

22Amended Consulting Agreement - Ronald Mink

 
Exhibit 4.1(g)

 
Amendment 1 to Consulting Agreement

Between Calypte Biomedical Corporation and Ronald W. Mink 
 
This Agreement amends and modifies the Consulting Agreement between Calypte Biomedical Corporation (“Calypte” or
the “Company”) and Creative BioSolutions/Ron Mink (“Consultant”) dated July 15, 2002 and is effective as of March 24, 2003. 
 
Whereas, the Company desires to change the payment terms on the contract and Consultant is agreeable to such modification. 
 
Now therefore, in consideration of the premises and mutual promises set forth
herein, the parties hereto agree as follows: 
 

	1.	 	The Company acknowledges that it owes Consultant $28,264.21 for services rendered, payable in cash. It will now convert these payments to stock issuable to
Consultant based on a value of approximately $0.025 per share for a total of 1,131,000 shares. 

 

	2.	 	In consideration for this modification, the Company agrees to register the shares with the upcoming S-8 filing during March 2003. If the filing occurs after March,
Consultant has the option to accept only cash. 

 

	3.	 	Further, the remaining shares included in the initial agreement as a stock bonus are now considered fully vested. 

 

	4.	 	All other terms and conditions of the Consultant Agreement dated July 15, 2002 remain unchanged. 

 

	 Consultant:
	 	 	 	 Calypte Biomedical Corporation

	
	 /s/    Ronald W. Mink

	 	 	 	 By:
	 	 /s/    Richard D. Brounstein

	 Ronald W. Mink
	 	 	 	 Richard D. Brounstein
 Executive Vice President, CFO

 
 
 

23Amended Consulting Agreement - Michael Sitrick

 
Exhibit 4.1(h)

 
Amendment 1 to Consulting Agreement

Between Calypte Biomedical Corporation and Sitrick 
 
This letter (“Letter”) when accepted by you as provided below will modify and amend the referenced
engagement letter (the “Engagement Letter”) between Sitrick And Company Inc., a California Corporation and its Principal, Michael Sitrick (“Sitrick”), and Calypte Biomedical Corporation, a Delaware corporation
(“Calypte” or the “Company”). 
 
Pursuant to the Engagement Letter Sitrick was retained to provide certain consulting and other services (the “Services”) to the Company (the “Engagement”). The Engagement was terminated by Calypte
effective as of October 25, 2002, at which time Calypte was indebted to Sitrick for unpaid fees related to Services rendered by Sitrick pursuant to the Engagement Letter plus expenses Sitrick incurred through that date (the “Debt”).
As part of Sitrick’s compensation under the Engagement Letter, Calypte was to issue to Sitrick, and cause to be registered under the Securities Act of 1933 as amended, as freely-tradable, 300,000 shares of its Common Stock (the
“Shares”) which Shares have been issued to Sitrick but not registered. 
 
The parties now wish to reinstate the Engagement and have Sitrick resume providing the Services, pursuant to the terms and conditions of the Engagement Letter as modified by this Letter, and to fully
and finally settle all differences related to the Debt and the Shares. 
 
Effective as of March 26, 2003, the parties reinstate the Engagement pursuant to the Engagement Letter, including the previously agreed-upon monthly retainer of $7,500 plus expenses for investor relations consulting services
(“IR Services”). The Company acknowledges the $7,500 is the minimum, non-refundable monthly fee retainer for Sitrick’s IR Services. The Company further acknowledges that for IR Services: (i) Sitrick’s time charges will be billed
against the retainer at the hourly rate range of $160 to $625, depending on the person performing the services; (ii) when the $7,500 monthly retainer has been fully applied against that month’s time charges, additional time charges for the
month will be billed as incurred; (iii) time charges are computed on a portal-to-portal basis for any travel time for meetings held outside of Sitrick’s offices; (iv) time is charged and billed by Sitrick in increments of one-quarter of an
hour; and (v) hourly rates are adjusted at the end of each calendar year. 
 
The Company also acknowledges and Sitrick agrees that Sitrick shall be compensated for any fees related to IR Services (based on time charges) incurred in a month that exceed the $7,500 monthly retainer, provided Sitrick has received
prior approval from Calypte to perform additional services. The $7,500 monthly retainer shall be due and payable on or prior to the first day of the calendar month to which it relates. Fees billed in excess of the retainer for that month shall be
due and payable within twenty days of invoice date. The retainer for March 2003 will be prorated as of the effective date of this Letter and payment made within three business days. 
 
The $7,500 monthly retainer is to cover time charges for IR Services and is not to cover time charges for
extraordinary projects as defined in the Engagement Letter. As with IR Services, the Company acknowledges that for extraordinary projects (i) Sitrick’s time charges will be billed at the hourly rate range of $160 to $625, depending on the
person performing the services, (ii) time charges are computed on a portal-to-portal basis for any travel time for meetings held outside of Sitrick’s offices; (iii) time is charged and billed by Sitrick in increments of one-quarter of an

 

24 

hour; and (iv) hourly rates are adjusted at the end of each calendar year. Time charges will be billed as
incurred and shall become due and payable within twenty days of invoice date. 
 
Payment for out of pocket expenses for Services remains as per the Engagement Letter. 
 
Calypte acknowledges it has not registered the Shares as freely-tradable as required by the Engagement Letter and that the Debt, which is due, owing and payable to Sitrick without offset, totals
$35,264.34 (comprised of $29,495.64 for past investor relations consulting services plus $5,768.70 for services on the extraordinary project related to the preparation of a public service announcement). Calypte agrees to settle the Debt and to
register the Shares in accordance with the following terms: 
 

	(i)	 	Calypte shall at its sole cost and expense cause the Shares to be registered under the Securities Act of 1933 as amended by filing an S-8 with the Securities and
Exchange Commission on or before March 28, 2003 or in lieu thereof, shall cause a like number of shares to be registered and issued to Sitrick by March 28, 2003 in exchange for the original Shares; 

 

	(ii)	 	Calypte acknowledges that it owes and shall satisfy the Debt ($35,264.34) through the issuance to Michael Sitrick, principal, or his assignee, of 1,500,000
registered, freely-tradable shares of Calypte Common Stock on or before March 28, 2003; 

 

	(iii)  In	 	the event the 1,500,000 shares are not registered by March 28, 2003 as required by (ii) above, then the full amount ($35,264.34) of the Debt shall be immediately due
and payable in cash, plus interest at the rate of 10% per annum from the date the amounts were past due. 

 
Except as modified by this Letter, the Engagement Letter is reinstated and operative without modification or amendment. 
 

	 SITRICK AND COMPANY INC.
	 	 	 	 CALYPTE BIOMEDICAL CORPORATION
 Agreed and accepted

	
	 By
	 	 /s/    Michael Sitrick

	 	 	 	 By
	 	 /s/    Richard D. Brounstein

	 Michael Sitrick
 Chairman and CEO
	 	 	 	 Richard D. Brounstein
 Executive Vice President and CFO

 

25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]